Literature DB >> 32645391

Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU.

Dong Zhang1, Xiang Zhou2, Songxin Yan1, Ran Tian3, Longxiang Su2, Xin Ding2, Meng Xiao1, Yu Chen1, Hua Zhao2, Huan Chen2, Hongmin Zhang2, Zunzhu Li2, Qi Li2, Yingchun Xu1, Xiaowei Yan3, Yongzhe Li4, Shuyang Zhang5.   

Abstract

BACKGROUND: The novel SARS-CoV-2 caused a large number of infections and deaths worldwide. Thus, new ideas for an appropriated assessment of patients' condition and clinical treatment are of utmost importance. Therefore, in this study, the laboratory parameters of patients with coronavirus disease 2019 (COVID-19) were evaluated to identify the correlation between cytokine expression and other laboratory parameters.
METHODS: A retrospective and single-center study was performed in Wuhan, involving 83 severe or critical COVID-19 patients admitted to the intensive care unit (ICU). Laboratory parameters in ICU patients with laboratory-confirmed infection of SARS-CoV2 were collected. The association between parameters was assessed by Spearman's rank correlation.
RESULTS: Patients' median age was 66 years (IQR, 57-73), and 55 (66%) were men. Among the 83 patients, 61 (73%) had 1 or more coexisting medical condition. The median concentration of IL-2R, IL-6, IL8, IL10, and TNFα were above the normal range, without IL-1β. A significant negative correlation between IL-6 and platelet count was discovered (r2 = -0.448, P < 0.001) as well as a significant correlation between IL-6 and other platelet parameters. Finally, a correlation between multiple cytokines and coagulation indicators was found, pro-inflammatory factors were found to be more associated to coagulation parameters, with the highest correlation between IL-6 and the International normalized ratio (INR) (r2 = 0.444, P < 0.001).
CONCLUSIONS: Our results suggested that cytokines play an important role in the pathogenesis of COVID-19. In addition, IL-6 seems more relevant in the evaluation of the condition of COVID-19 patients.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; Coagulation; Correlation; Cytokines; IL-6

Mesh:

Substances:

Year:  2020        PMID: 32645391     DOI: 10.1016/j.cca.2020.07.002

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Coagulopathies in novel coronavirus (SARS-CoV-2) pandemic: emerging evidence for hematologists.

Authors:  Abeer M AlSubaie
Journal:  Saudi J Biol Sci       Date:  2020-11-05       Impact factor: 4.219

2.  Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.

Authors:  Haijun Xiong; Zhaowei Dong; Guanhua Lou; Qingxia Gan; Jin Wang; Qinwan Huang
Journal:  Eur J Integr Med       Date:  2020-10-30       Impact factor: 1.314

3.  A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis.

Authors:  Nobuyasu Ishii; Toshiki Shimizu; Yoshihisa Ishiura; Hideki Amuro; Tohru Nishizawa; Takeshi Tamaki; Shosaku Nomura
Journal:  J Inflamm Res       Date:  2021-08-05

4.  Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population.

Authors:  Sara Falahi; Mohammad Hossein Zamanian; Parisa Feizollahi; Alireza Rezaiemanesh; Farhad Salari; Zahra Mahmoudi; Ali Gorgin Karaji
Journal:  Cytokine       Date:  2022-04-19       Impact factor: 3.926

5.  Relative expression of proinflammatory molecules in COVID-19 patients who manifested disease severities.

Authors:  Shireen Nigar; Sm Tanjil Shah; Md Ali Ahasan Setu; Sourav Dutta Dip; Habiba Ibnat; M Touhidul Islam; Selina Akter; Iqbal Kabir Jahid; M Anwar Hossain
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

Review 6.  Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.

Authors:  Muhammad Aslam; Yury Ladilov
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

7.  A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.

Authors:  Brian Eka Rachman; Andang Miatmoko; Soroy Lardo; Yongki Iswandi Purnama; Mafidhatul Laely; Ike Rochmad; Taufik Ismail; Sri Wulandari; Dwi Setyawan; Alfian Nur Rosyid; Herley Windo Setiawan; Prastuti Asta Wulaningrum; Tri Pudy Asmarawati; Erika Marfiani; Shinta Karina Yuniati; Muhammad Rabiul Fuadi; Pepy Dwi Endraswari; Eryk Hendrianto; Deya Karsari; Aristika Dinaryanti; Nora Ertanti; Igo Syaiful Ihsan; Disca Sandyakala Purnama; Yuni Indrayani
Journal:  Biochem Res Int       Date:  2021-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.